vzphotos/iStock Editorial via Getty Images AbbVie (NYSE:ABBV) shares traded in the red on Thursday, making
hapabapa/iStock Editorial via Getty Images Leerink Partners upgraded Bristol-Myers Squibb (NYSE:BMY) to Outperform from Market
Summary: AbbVie investors that bought the anxiety over the loss of Humira exclusivity are sitting
Summary: AbbVie shares dropped nearly 10% after its schizophrenia drug emraclidine failed in late-stage trials.
Michael Vi/iStock Editorial via Getty Images AbbVie (NYSE:ABBV) and its shareholders were dealt a major
Summary: Emraclidine’s failure in phase 2 trials is a significant setback for AbbVie’s neuroscience pipeline.
hapabapa AbbVie (NYSE:ABBV) shares dropped about 11% after its late-stage trials investigating emraclidine as an
Easyturn/iStock via Getty Images Momentum is currently a key factor when investing, according to Oppenheimer
Edwin Tan Companies that grabbed headlines in the deals space include: AbbVie (NYSE:ABBV) has agreed
Summary: It is no surprise investors have responded positively to AbbVie’s latest results considering revenue